alexa

GET THE APP

Irinotecan-Based Regimen as Second-Line Chemotherapy for Extensive-Stage Small Cell Lung Cancer | OMICS International| Abstract
ISSN: 2476-2253

Journal of Cancer Diagnosis
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • J Cancer Diagn 2016, Vol 1(1): 102
  • DOI: 10.4172/2476-2253.1000102

Irinotecan-Based Regimen as Second-Line Chemotherapy for Extensive-Stage Small Cell Lung Cancer

Guoping Cheng1 and Lei Shi2*
1Department of Pathology, Zhejiang Cancer Hospital, , Hangzhou, PR China
2Department of Chemotherapy, Zhejiang Cancer Hospital, , Hangzhou 310022, PR China
*Corresponding Author : Lei Shi, Department of Chemotherapy, Zhejiang Cancer Hospital, 38 Guangji Road 310022, Hangzhou, PR China, Tel: +8657188122182, Fax: +8657188122188, Email: [email protected]

Received Date: Jan 01, 2016 / Accepted Date: Jan 28, 2016 / Published Date: Nov 12, 2016

Abstract

Purpose: This study evaluates the clinical outcomes of extensive-stage small-cell lung cancer (SCLC) patients who received Irinotecan-based second-line chemotherapy after platinum-based first-line therapy, especially focused on efficacy and toxicity between single-agent and doublet chemotherapy.

Patients and methods: We retrospectively reviewed 83 patients who given irinotecan-based second-line chemotherapy for extensive-stage SCLC. Survival curves were plotted using the Kaplan–Meier method. The Cox proportional hazard model was used for multivariate analysis.

Results: Fifty-nine patients received doublet chemotherapy and 24 with single-agent treatment. The objective response rate (ORR) was 23.7% in the doublet group and 25% in the single-agent group (P=0.90). The disease control rate (DCR) was 65.7% and 58.3%, respectively, (P=0.71). The Progression-free survival (PFS) was 3.10 months in the doublet group and 2.10 months in the single-agent group (P=0.35). In the sensitive recurrence group, 27 patients were with doublet chemotherapy and 10 with single-agent treatment. The Median PFS was 4.73 months (95% CI: 4.37-5.09) and 3.83months (95% CI: 2.65-5.02), respectively (P=0.543). In the refractory recurrence group, there were 32 patients with doublet chemotherapy and 14 with single-agent treatment. The median PFS was 2.57 months (95% CI: 2.19-2.93) and 1.40 months (95% CI: 1.13-1.64), respectively (P=0.048). The grade III/IV toxicity in single-agent group is lower than doublet group (45.8% vs.71.2%, P=0.029). No difference was found in cancerrelated symptoms improvement between the doublet and single group (P=0.36).

Conclusion: Patients with extensive-stage SCLC could benefit from irinotecan-based second-line treatments. The refractory recurrence patients with doublet treatment obtain a moderate PFS advantage than single-agent chemotherapy.

Keywords: Small cell lung cancer; Second-line; Irinotecan; Efficacy

Citation: Cheng G, Shi L (2016) Irinotecan-Based Regimen as Second-Line Chemotherapy for Extensive-Stage Small Cell Lung Cancer. J Cancer Diagn 1:102. Doi: 10.4172/2476-2253.1000102

Copyright: © 2016 Cheng G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Article Usage
  • Total views: 10467
  • [From(publication date): 6-2016 - Oct 23, 2021]
  • Breakdown by view type
  • HTML page views: 10167
  • PDF downloads: 300

Review summary

  1. Cameron Barajas
    Posted on Sep 15 2016 at 11:46 am
    The article investigates the effectiveness and toxicity of irinotecan alone or in combination with platinum agents as second-line treatment in patients with SCLC. They report that irinotecan had moderated efficacy in second-line therapy, and warrants further studies.
Top